CRISPR Therapeutics AG (CRSP) Depreciation and Depletion (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Depreciation and Depletion data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion fell 8.51% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $18.9 million (down 1.05% YoY), and the FY2025 full-year result was $19.4 million, up 1.04% from the prior year.
• Depreciation and Depletion eased to $4.3 million in Q1 2026, from $5.6 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $7.3 million in Q2 2022 to a low of $4.3 million in Q1 2026.
• A 5-year average of $5.1 million and a median of $4.9 million in 2023 frame the typical range for Depreciation and Depletion.
• Across the five-year window, Depreciation and Depletion soared 122.22% in 2022 and plunged 31.51% in 2023, its largest moves.
• Tracing CRSP's Depreciation and Depletion over 5 years: stood at $5.8 million in 2022, then dropped by 15.52% to $4.9 million in 2023, then slipped by 2.04% to $4.8 million in 2024, then climbed by 16.67% to $5.6 million in 2025, then fell by 23.21% to $4.3 million in 2026.
• Business Quant data shows CRSP's Depreciation and Depletion at $4.3 million in Q1 2026, $5.6 million in Q4 2025, and $4.4 million in Q3 2025.